Select Page

Spinal Muscular Atrophy ConferenceLa Conférence sur l'Amyotrophie Spinale

Samedi 11 novembre  |  Saturday November 11, 2017
12 pm—2 pm Séance en français  |  3 pm—5 pm English Session
De Grandpre Communications Centre, The MNI, 3801 University Street, Montreal, Quebec
The Spinal Muscular Atrophy Conference will feature presentations on advancements in the treatment of SMA, research, and clinical trials presented by neurologists and CRU staff.

Approval of Spinraza for Spinal Muscular atrophy (SMA)

“A game changing drug could save hundreds of Canadian kids with spinal muscular atrophy (SMA) from a life of profound disability…

The Neuro to create world’s first ALS Phase 1 clinical trial unit

“The establishment of a Phase 1 clinical trial unit will give ALS patients in Quebec and Canada first line access to the newest innovations,” -Dr. Angela Genge

Welcome to the Clinical Research Unit at the Montreal Neurological Institute and Hospital

The Clinical Research Unit (CRU) is part of McGill University and is located in the Montreal Neurological Institute & Hospital (MNI/MNH). This building, conceived by Dr. Wilder Penfield, comprises the MNI, a teaching and research institute, and the MNH, which is part of the McGill University Health Centre (MUHC). Inside its walls scientists and clinicians strive to bring better quality of care to the population through basic and clinical research including new surgical methods. This is the ideal location for the CRU since it can offer participation in clinical trials to the thousands of inpatients and outpatients that pass through the MNH every year.
Through McGill and the MUHC, the CRU has access to the most advanced medical technology available today. The CRU conducts clinical trials sponsored by pharmaceutical companies or granting agencies such as the National Institutes of Health (NIH) in the USA. All experimental medications used in clinical trials have already been tested in animals and in humans. All clinical trials have been approved by Health Canada (also FDA if conducted in USA) and have passed a rigorous review by the MNI/MNH Research Ethics Board.

Dedicated To:
• Aiding the advancement of neuroscience through clinical research.
• Participating in clinical trials to identify new or more effective treatments.
• Supplying study subjects with the best quality of care.

• Providing high quality data to sponsors and investigators.